<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04106297</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG3970-CL-101</org_study_id>
    <secondary_id>2019-001803-19</secondary_id>
    <nct_id>NCT04106297</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970</brief_title>
  <official_title>A First-in-human, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GLPG3970 Single and Multiple Ascending Doses in Adult Healthy Male Subjects, and in Psoriasis Subjects When Administered Daily for 6 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and tolerability of GLPG3970 in&#xD;
      healthy volunteers after single oral administrations of GLPG3970 (SAD), compared to placebo&#xD;
      (part 1 and 1bis) and after multiple (for 14 days) oral administrations of GLPG3970 (MAD),&#xD;
      compared to placebo (part 2). The effect of food (FE) (high-fat, high calorie) on the&#xD;
      pharmacokinetics of GLPG3970 and the relative bioavailability (rBA) of an oral solution&#xD;
      versus a solid formulation will be assessed (part 3 and 3bis). Part 4 of the study is to&#xD;
      evaluate the safety and tolerability of GLPG3970 in subjects with moderate to severe&#xD;
      psoriasis when administered daily for 6 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Actual">March 5, 2021</completion_date>
  <primary_completion_date type="Actual">March 5, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part 1 and 1bis (SAD), Part 2 (MAD) and Part 4 (psoriasis subjects) are randomized, double-blind, placebo-controlled; Part 3 (FE-rBA) and Part 3bis (FE) are randomized, open-label.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events (TEAEs), treatment-emergent serious adverse events, and TEAEs leading to treatment discontinuations</measure>
    <time_frame>From screening through study completion, an average of 20 months</time_frame>
    <description>To evaluate the safety and tolerability of GLPG3970 compared to placebo in adult healthy male subjects as single and multiple ascending oral doses, and in subjects with moderate to severe psoriasis when administered daily for 6 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of GLPG3970 (Part 1 and 1bis)</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To evaluate the pharmacokinetics (PK) of oral SAD of GLPG3970 in adult healthy male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of GLPG3970 (Part 2)</measure>
    <time_frame>Between Day 1 pre-dose and Day 17</time_frame>
    <description>To evaluate the PK of oral MAD of GLPG3970 in adult healthy male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of GLPG3970 (Part 3 and 3bis, FE)</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To evaluate the food effect on the PK of a single oral dose of GLPG3970 in adult, healthy, subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of GLPG3970 (Part 3, rBA)</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To evaluate the PK of a single oral dose of GLPG3970 administered as an oral solution versus and oral capsule in adult, healthy, subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under curve (AUC) of GLPG3970 (Part 1 and 1bis)</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To evaluate the PK of oral SAD of GLPG3970 in adult healthy male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under curve (AUC) of GLPG3970 (Part 2)</measure>
    <time_frame>Between Day 1 pre-dose and Day 17</time_frame>
    <description>To evaluate the PK of oral MAD of GLPG3970 in adult healthy male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under curve (AUC) of GLPG3970 (Part 3 and 3bis, FE)</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To evaluate the food effect on the PK of a single oral dose of GLPG3970 under fed conditions (high-fat high calorie) versus fasted conditions in adult, healthy, subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under curve (AUC) of GLPG3970 (Part 3, rBA)</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To evaluate the rBA of an oral solution of GLPG3970 versus an oral capsule of GLPG3970 on the PK of a single oral dose of GLPG3970 in adult, healthy, subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2) of GLPG3970 (Part 1 and 1bis)</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To evaluate the PK of oral SAD of GLPG3970, in adult, healthy, subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2) of GLPG3970 (Part 2)</measure>
    <time_frame>Between Day 1 pre-dose and Day 17</time_frame>
    <description>To evaluate the PK of oral MAD of GLPG3970, in adult, healthy, subjects</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Healthy</condition>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>GLPG3970 SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single doses of GLPG3970 at up to 6 dose levels in ascending order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3970 MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of GLPG3970 at up to 4 dose levels in ascending order, daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3970 FE-rBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of GLPG3970 in fed and fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3970 FE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of GLPG3970 in fed and fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3970 in psoriasis subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in psoriasis subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3970 oral solution</intervention_name>
    <description>GLPG3970 for oral administration</description>
    <arm_group_label>GLPG3970 FE</arm_group_label>
    <arm_group_label>GLPG3970 FE-rBA</arm_group_label>
    <arm_group_label>GLPG3970 MAD</arm_group_label>
    <arm_group_label>GLPG3970 SAD</arm_group_label>
    <arm_group_label>GLPG3970 in psoriasis subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral solution</intervention_name>
    <description>Placebo for oral administration</description>
    <arm_group_label>Placebo MAD</arm_group_label>
    <arm_group_label>Placebo SAD</arm_group_label>
    <arm_group_label>Placebo in psoriasis subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3970 capsule</intervention_name>
    <description>GLPG3970 for oral administration</description>
    <arm_group_label>GLPG3970 FE-rBA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Part 1, 1bis, 2, 3 and 3bis:&#xD;
&#xD;
          -  Male between 18-55 years of age (extremes included), on the date of signing the&#xD;
             informed consent form (ICF).&#xD;
&#xD;
          -  A body mass index (BMI) between 18-30 kg/m2, inclusive.&#xD;
&#xD;
          -  Judged to be in good health by the investigator based upon the results of a medical&#xD;
             history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and&#xD;
             fasting clinical laboratory safety tests available at screening and prior to&#xD;
             randomization. Hemoglobin must not be below the lower limit of normal range.&#xD;
             Bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) must&#xD;
             be no greater than 1.5x upper limit of normal range (ULN). Other clinical laboratory&#xD;
             safety test results must be within the reference ranges, or test results that are&#xD;
             outside the reference ranges need to be considered not clinically significant in the&#xD;
             opinion of the investigator.&#xD;
&#xD;
        This list only contains the key inclusion criteria for the healthy volunteers part of the&#xD;
        study.&#xD;
&#xD;
        Inclusion criteria for Part 4:&#xD;
&#xD;
          -  Male or female between 18-65 years of age (extremes included), on the date of signing&#xD;
             the ICF.&#xD;
&#xD;
          -  Diagnosed with plaque psoriasis ≥6 months.&#xD;
&#xD;
          -  Screening Psoriasis Area and Severity Index (PASI) ≥12 (moderate to severe) and&#xD;
             affected body surface area (BSA) ≥10%.&#xD;
&#xD;
          -  A body mass index (BMI) between 18-35 kg/m2, inclusive.&#xD;
&#xD;
        This list only contains the key inclusion criteria for Part 4 of the study.&#xD;
&#xD;
        Exclusion Criteria for Part 1, 1bis, 2, 3 and 3bis:&#xD;
&#xD;
          -  Known hypersensitivity to the Investigational Medicinal Product (IMP) ingredients or&#xD;
             history of a significant allergic reaction to IMP ingredients as determined by the&#xD;
             investigator.&#xD;
&#xD;
          -  Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus&#xD;
             or history of hepatitis from any cause with the exception of hepatitis A that was&#xD;
             resolved at least 3 months prior to first dosing of the IMP.&#xD;
&#xD;
          -  History of or a current immunosuppressive condition (e.g. human immunodeficiency virus&#xD;
             [HIV] infection).&#xD;
&#xD;
        This list only contains the key exclusion criteria for the healthy volunteers part of the&#xD;
        study.&#xD;
&#xD;
        Exclusion criteria for Part 4:&#xD;
&#xD;
          -  Subject has evidence of skin conditions other than psoriasis (e.g., eczema) at the&#xD;
             time of screening or baseline visit that would interfere with the evaluation of&#xD;
             psoriasis.&#xD;
&#xD;
          -  Subject is unable to discontinue systemic therapies and/or topical therapies for the&#xD;
             treatment of psoriasis and cannot discontinue phototherapy (UVB or PUVA) from signing&#xD;
             of the ICF up to the end of the study.&#xD;
&#xD;
        This list only contains the key inclusion criteria for Part 4 of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdalena Petkova, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Belgium NV - Clinical Pharmacology Unit Antwerp</name>
      <address>
        <city>Antwerp</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Republican Hospital Arensia Experimental Medicine</name>
      <address>
        <city>Chisinau</city>
        <zip>MD2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARENSIA Exploratory Medicine Unit</name>
      <address>
        <city>Kyiv</city>
        <zip>01135</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Moldova, Republic of</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

